Displaying 1061 - 1080 of 1505
Fresenius AG, In the Matter of
Fresenius AG settled charges that its purchase of rival dialysis provider Renal Care Group, Inc. would likely have resulted in higher prices for dialysis services. The consent order requires that Fresenius AG will sell 91 outpatient kidney dialysis clinics and financial interests in 12 more.
FTC Approves Final Consent Order in Matter of Fresenius and Renal Care
FTC Staff: Alpena, Michigan, Public Schools Planned Pharmaceutical Transfer Falls Within NPIA; Final Consent Orders Approved in Matters of Nations Title and Basic Research Consumer Protection Matters
Johnson & Johnson, In the Matter of
The consent order protects competition in three medical device product markets affected by Johnson & Johnson’s proposed $25.4 billion acquisition of Guidant Corporation. Under the terms of the order, J&J is required to 1) grant to a third party a 6 fully paid-up, non-exclusive, irrevocable license, enabling that third party to make and sell drug eluting stents with the Rapid Exchange delivery system, 2) divest to a third party J&J’s endoscopic vessel harvesting product line, and 3) end its agreement to distribute Novare Surgical System, Inc.’s proximal anastomotic assist device. On May 31st, 2006 the Commission granted a petition filed by Johnson and Johnson Corporation, requesting that the FTC reopen and set aside the entire decision and order concerning the proposed acquisition of Guidant Corporation.
Commission Approves Divestiture in Matter of DaVita/Gambro; FTC Approves Petition for Sale of Meow Mix Company to Del Monte Corporation; Final Consent Order Approved in Matter of Dynamic Health of Florida
DaVita, Inc.
Exclusion Payments to Settle Pharmaceutical Patent Cases: They're B-a-a-a-ck!
Bureau of Competition Issues FY 2005 Summary of Pharmaceutical Company Settlement Agreements
Allergan, Inc., and Inamed Corporation, In the Matter of
The consent order requires that Allergan and Inamed divest the rights to develop and distribute Reloxin, a potential Botox rival, to settle charges that Allergan’s $3.2 billion purchase of Inamed would reduce competition and force consumers to pay higher prices for botulinum toxin type A products. Under the terms of the FTC settlement, the companies will return the development and distribution rights to Reloxin to Ipsen Ltd., its U.K.- based manufacturer.
Commission Approves Final Consent Order in Matter of Allergan/Inamed
Maintaining Competition, FTC Allows Fresenius $3.5 Billion Deal to Buy Rival Dialysis Provider Renal Care Group
FTC Proposes Study of Competitive Impacts of Authorized Generic Drugs
Hospitals Plan for Collective Bargaining of Physicians Fees Likely Would Violate Federal Laws, FTC Staff Says
Health Care Alliance of Laredo, L.C., In the Matter of
Preserving Competition, FTC Requires Divestiture Before Allowing Allergans Acquisition of Inamed
Teva Pharmaceutical Industries Ltd. and IVAX Corporation, In the Matter of
The consent order allowed Teva to acquire IVAX Corporation, provided the companies sell the rights and assets needed to manufacture and market 15 generic pharmaceutical products. Among the drugs sold were several forms of generic amoxicillin and amoxicillin clavulanate potassium that are widely used in the United States.
FTC Staff Files Comments on New Jerseys Proposed Advertising Guideline 4; Commission Finalizes Teva/Ivax Consent Order
Texas Doctors' IPA Agrees to Settle Price Fixing Charges
Displaying 1061 - 1080 of 1505